Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin, 57460 [E9-26787]

Download as PDF 57460 Federal Register / Vol. 74, No. 214 / Friday, November 6, 2009 / Notices Annual Burden Hours: 4,100. Needs and Uses: The information collection requirement is necessary to obtain data on candidate’s background and aptitude in determining eligibility and selection to the Air Force Academy. Affected Public: Individuals or households. Frequency: On occasion. Respondent’s Obligation: Required to obtain or retain benefits. OMB Desk Officer: Ms. Jasmeet Seehra. Written comments and recommendations on the proposed information collection should be sent to Ms. Seehra at the Office of Management and Budget, Desk Officer for DoD, Room 10236, New Executive Office Building, Washington, DC 20503. You may also submit comments, identified by docket number and title, by the following method: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. Instructions: All submissions received must include the agency name, docket number and title for this Federal Register document. The general policy for comments and other submissions from members of the public is to make these submissions available for public viewing on the Internet at https:// www.regulations.gov as they are received without change, including any personal identifiers or contact information. DOD Clearance Officer: Ms. Patricia Toppings. Written requests for copies of the information collection proposal should be sent to Ms. Toppings at WHS/ESD/ Information Management Division, 1777 North Kent Street, RPN, Suite 11000, Arlington, VA 22209–2133. invention set forth in U.S. Provisional Patent Application Serial No. 61/ 252,675 entitled ‘‘Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin,’’ filed October 18, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to the use of enhanced substrates for the protease activity of serotype A botulinum neurotoxin. Dated: October 26, 2009. Patricia L. Toppings, OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. E9–26706 Filed 11–5–09; 8:45 am] ACTION: BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE mstockstill on DSKH9S0YB1PROD with NOTICES6 Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin Department of the Army, DoD. Notice. AGENCY: ACTION: SUMMARY: Announcement is made of the availability for licensing of the VerDate Nov<24>2008 18:23 Nov 05, 2009 Jkt 220001 Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. E9–26787 Filed 11–5–09; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Methods and Composition for Live Bubonic Plague Vaccine Based on Yersinia Pestis * * * Gene Deletion Department of the Army, DoD. Notice. AGENCY: SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 242,113 entitled ‘‘Methods and Composition for Live Bubonic Plague Vaccine Based On Yersinia Pestis * * * Gene Deletion,’’ filed September 14, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of PO 00000 Frm 00014 Fmt 4703 Sfmt 4703 Research and Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034. The invention relates to the creation of live vaccines by removing a specific gene, which is essential for virulence (the ability of a pathogen to make sick or kill a human or an animal) from a pathogen. SUPPLEMENTARY INFORMATION: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. E9–26790 Filed 11–5–09; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army; Corps of Engineers Inland Waterways Users Board AGENCY: Department of the Army, U.S. Army Corps of Engineers, DoD. ACTION: Notice of open meeting. SUMMARY: In accordance with 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), announcement is made of the forthcoming meeting. Name of Committee: Inland Waterways Users Board (Board). Dates: December 15, 2009. Location: The Westin New Orleans Canal Place, 100 Rue Iberville, New Orleans, Louisiana 70130 (504–566–7006 or 1–888– 627–8180). Time: Registration will begin at 8 a.m. and the meeting is scheduled to adjourn at approximately 1 p.m. Agenda: The Board will hear the results of the Inland Marine Transportation System (IMTS) Investment Strategy Team activities, as well as the status of the funding for inland navigation projects and studies and the status of the Inland Waterways Trust Fund. FOR FURTHER INFORMATION CONTACT: Mr. Mark R. Pointon, Headquarters, U.S. Army Corps of Engineers, CECW–ID, 441 G Street, NW., Washington, DC 20314–1000; Ph: 202–761–4691. The meeting is open to the public. Any interested person may attend, appear before, or file statements with the committee at the time and in the manner permitted by the committee. SUPPLEMENTARY INFORMATION: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. E9–26786 Filed 11–5–09; 8:45 am] BILLING CODE 3720–58–P E:\FR\FM\06NON1.SGM 06NON1

Agencies

[Federal Register Volume 74, Number 214 (Friday, November 6, 2009)]
[Notices]
[Page 57460]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26787]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Application Concerning Enhanced 
Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/252,675 entitled ``Enhanced Substrates for the Protease Activity of 
Serotype a Botulinum Neurotoxin,'' filed October 18, 2009. The United 
States Government, as represented by the Secretary of the Army, has 
rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Assessment, (301) 619-6664, 
both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to the use of enhanced 
substrates for the protease activity of serotype A botulinum 
neurotoxin.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-26787 Filed 11-5-09; 8:45 am]
BILLING CODE 3710-08-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.